Regulus Therapeutics Stock Alpha and Beta Analysis
| RGLS Stock | USD 1.61 0.03 1.83% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Regulus Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Regulus Therapeutics over a specified time horizon. Remember, high Regulus Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Regulus Therapeutics' market risk premium analysis include:
Beta 0.94 | Alpha (0.09) | Risk 4.11 | Sharpe Ratio 0.0297 | Expected Return 0.12 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Regulus |
Regulus Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Regulus Therapeutics market risk premium is the additional return an investor will receive from holding Regulus Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Regulus Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Regulus Therapeutics' performance over market.| α | -0.09 | β | 0.94 |
Regulus Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Regulus Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Regulus Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Regulus Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Regulus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Regulus Therapeutics shares will generate the highest return on investment. By understating and applying Regulus Therapeutics stock market price indicators, traders can identify Regulus Therapeutics position entry and exit signals to maximize returns.
Regulus Therapeutics Return and Market Media
The median price of Regulus Therapeutics for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 is 1.54 with a coefficient of variation of 5.5. The daily time series for the period is distributed with a sample standard deviation of 0.08, arithmetic mean of 1.54, and mean deviation of 0.07. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Regulus Consolidates 100 percent Ownership of the Colquirrumi Claims | 10/10/2024 |
2 | Acquisition by Witz Pascale of 90000 shares of Regulus Therapeutics at 0.27 subject to Rule 16b-3 | 10/18/2024 |
3 | HC Wainwright Reiterates Buy Rating for Regulus Therapeutics - MarketBeat | 10/30/2024 |
4 | Vanguard Group Incs Strategic Acquisition in Regulus Therapeutics Inc | 11/05/2024 |
5 | Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates | 11/07/2024 |
6 | Biotechnology Value Fund L.P. Increases Stake in Regulus Therapeutics Inc | 11/15/2024 |
7 | Acquisition by Nunn Jason Raleigh of 30000 shares of Regulus Therapeutics at 1.45 subject to Rule 16b-3 | 11/22/2024 |
8 | Top TSX Penny Stocks To Watch In November 2024 | 11/25/2024 |
About Regulus Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Regulus or other stocks. Alpha measures the amount that position in Regulus Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Graham Number | 6.31 | 6.0 | Receivables Turnover | 22.88 | 42.26 |
Regulus Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Regulus Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Regulus Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Regulus Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Regulus Therapeutics. Please utilize our Beneish M Score to check the likelihood of Regulus Therapeutics' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Regulus Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.